Infliximab(anti human TNF alfa monoclonal antibody, Remicade) off-label treatment for refractory Kawasaki disease

Infliximab(anti human TNF alfa monoclonal antibody, Remicade) off-label treatment for refractory Kawasaki disease - Infliximab treatment for refractory Kawasaki Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007423

Enrollment

Registered

2012-03-01

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kawasaki disease

Interventions

infliximab treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Kawasaki disease who do not respond to 2 cycles of high-dose gamma globulin and steroid pulse therapy, who do not respond to single cycle of high-dose gamma globulin with steroid and steroid pulse therapy, or who do not respond to 2 cycles of high-dose gamma globulin with steroid

Exclusion criteria

Exclusion criteria: congestive heart failure, severe infection, active tuberculosis, hypersensitivity for mouse-derived protein, demyelinating decease

Design outcomes

Primary

Measure	Time frame
Coronary artery abnormality after infliximab treatment	—

Secondary

Measure	Time frame
duration of fever	—

Countries

Japan

Contacts

Public ContactKoichi Moriwaki

Saitama Medical Center, Saitama Medical University Department of Pediatrics

kmoriwa@saitama-med.ac.jp049-228-3617

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026